REDWOOD CITY, CA (October 12, 2004) – Codexis, Inc. announcedthis week that Peter Ketelaar has joined the company as director of businessdevelopment, Europe.

In his new position, Ketelaar will be responsible for leading new business development activities in Europe, focusing on industry leaders in the pharmaceutical and life sciences sectors.

Specifically, he is expected to expand awareness and demand for Codexis’ MolecularBreeding platform, based on proprietary “DNAShuffling” technologyto reduce the cost of goods and manufacturing and extend a product’s life cycle, the company said.

Ketelaar joins Codexis from DSM Biologics, where he most recently held the position of director, new business development for Europe and Asia. During his 19-year tenure at DSM, Ketelaar conducted a variety of commercial activities, including worldwide marketing and sales, strategic business planning and market analysis, as well as new business development.

Ketelaar also served as chairman of DSM’s corporate business ethics committee. Prior to his commercial experience, he had a leading role at DSM Research, focusing on optimization of enzyme utilization in DSM’s amino acid manufacturing process.

Codexis’ proprietary DNAShuffling and MolecularBreeding directed molecular evolution technology uses biocatalysis and fermentation to enable discovery and development of processes for synthesis of pharmaceuticals and chemical compounds.

Codexis, Inc., a majority owned subsidiary of Maxygen, Inc., began operations as an independent company in 2002. Codexis provides biocatalysis and fermentation processes and products to the life sciences, chemical and allied industries.